Replies to post #147377 on Cytodyn Inc (CYDY)

[CTMedic]

Kgro,

I disagree, again.

CD12 has not exclusions based on CRP, which as you note is a good predictor of mortality, though I do not concur that it is the strongest predictor despite circumstantial evidence.

It is difficult to appreciate your saying, essentially in the same breath that:

The reason Cytodyn’s trial excludes high-risk patient is not related to CRP but to CD12’s inclusion criteria number 3.

(We know that CD12 included ventilated patients and patient on ECMO, just not the worst ARDS with simultaneous low PaO2/FiO2 ration and high PEEP


and

Hence why you see non ventilated patients yet a high mortality./quote]


While CD12 exclusion of patients with high CRP is listed here:

Exclusion Criteria:
Subjects with do-not-resuscitate (DNR) and/or do-not-intubate (DNI) orders or expected to be made DNR/DNI in setting of resource limitations or family wishes.
Not a candidate for dialysis or continuation of care (or full medical support) in setting of resource limitations.
Subject on continuous vasopressors (at the dose of norepinephrine >20µg/min and/or vasopressin >0.04 units/kg/min) for >48 hours at time of screening.
Subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible.
Inability to provide informed consent or to comply with test requirements
Consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment
Pregnancy or breast feeding
Subject participating in another study with for an investigational treatment for COVID-19.

Wait, what?

There is not mention of CRP?

My mistake.

So, we are back to CD12 data results.

Last, we would all know by now if Leronlimab had helped reduce mortality.

We do know that Leronlimab reduced mortality from Covid, as was demonstrated here in peer reviewed accounts of EIND administration.

https://www.sciencedirect.com/science/article/pii/S2589909021000034
https://www.ijidonline.com/article/S1201-9712(20)32305-5/fulltext
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277?guestAccessKey=876593f7-5e14-4e80-813c-01470f5fcd31

For definitive, unequivocal proof, we must wait (surely not much longer!) for the results of the pivotal CD12 trial.

Patience!